Archives: Agenda

How the right targeted communication and navigation favorably impacts clinical trial recruiting that is commensurate with the burden of disease

• Strategies for setting your trial apart from ones with similar eligibility criteria
• When the demand for patients is growing and supply is failing to keep up, what can be done for competing trials?
• Ways to differentiate from competitors without compromising patient safety
• Successfully navigating competitive oncology landscapes

• Overview of IO Biotech’s cancer vaccine clinical development strategy and ongoing Phase 2/3 programs across melanoma, lung, and head and neck cancer
• Key clinical milestones, including enrolment completion and efficacy/safety outcomes with vaccine + anti PD 1 combinations
• Operational considerations for executing multi cohort, global vaccine trials with complex neoadjuvant/adjuvant endpoints
• Insights on aligning clinical execution with regulatory strategy and preparing for potential registrational milestones

• Changing how researchers select potential patients for better success rates
• How has regulatory changed and what to expect?
• How to improve drug efficacy and patient safety before it’s too late
• Back to square one: Differentiating with simpler, patient-centric protocols and optimized study design
• Avoiding disappointing results by implementing the right technology tools to advance your trial
• Lessons learned to mitigate trial failures

Moderator: Keya Watkins, President – Oncology, Worldwide Clinical Trials